Generic Name and Formulations:
Betaine anhydrous 1g; per scoopful; pwd for dilution and oral administration.
Rare Disease Therapeutics, Inc.
Indications for CYSTADANE:
For the treatment of homocystinuria (eg, cystathionine beta-synthase [CBS] deficiency, 5, 10-methylenetetrahydrofolate reductase [MTHFR] deficiency, cobalamin cofactor metabolism [cbl] defect) to decrease elevated homocysteine blood levels.
Adults and Children:
Dissolve one scoop (1g betaine anhydrous pwd) in 4–6 ounces of water, juice, milk, formula, or mixed with food for immediate ingestion. <3yrs: initially 100mg/kg/day divided in twice daily doses, may increase weekly by 50mg/kg increments. ≥3yrs: 3g twice daily. Increase gradually until plasma total homocysteine is undetectable or present only in small amounts. Up to 20g/day has been used.
Hypermethioninemia. Monitor plasma methionine concentrations in patients with CBS deficiency. Pregnancy (Cat.C). Nursing mothers.
GI upset; hypermethioninemia, cerebral edema.
Bottle—180g (w. measuring scoop)
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy